20.1 Acute Respiratory Distress Syndrome (ARDS) and Mechanical Ventilation Strategies

20.1 Acute Respiratory Distress Syndrome (ARDS) and Mechanical Ventilation Strategies

Acute Respiratory Distress Syndrome (ARDS) is a life-threatening form of acute, diffuse, inflammatory lung injury characterized by increased pulmonary vascular permeability, severe alveolar flooding, loss of aerated lung tissue, and refractory arterial hypoxemia. For the EDAIC Part I examination, candidates must master the diagnostic classification, pathobiology, mechanical ventilator mechanics, and evidence-based adjunctive interventions.

---

The Berlin Definition of ARDS (2012)

The Berlin definition refined the earlier American-European Consensus Conference (AECC) criteria by removing the ambiguous term "acute lung injury" (ALI), mandating positive end-expiratory pressure (PEEP), and establishing three severity categories based on arterial oxygenation.

Note on High Altitude: At altitudes above 1,000 metres, the $P_a\text{O}_2/F_i\text{O}_2$ ratio must be multiplied by $(\text{Atmospheric Pressure in mmHg} / 760)$ to standardize the severity grade.

The 2024 Global Definition of ARDS

A 2023 international consensus (Matthay et al., American Journal of Respiratory and Critical Care Medicine 2024) broadened the Berlin definition so that it can be applied to more patients and settings:

• Non-intubated ARDS: Patients receiving high-flow nasal oxygen at $\ge 30\text{ L/min}$, or non-invasive ventilation/CPAP with end-expiratory pressure $\ge 5\text{ cm}\text{H}_2\text{O}$, with $P_a\text{O}_2/F_i\text{O}_2 \le 300\text{ mmHg}$ or $S_p\text{O}_2/F_i\text{O}_2 \le 315$ (the oxygen saturation ratio is valid only when $S_p\text{O}_2 \le 97\%$).
• Intubated ARDS: Severity is graded as mild ($200 < P_a\text{O}_2/F_i\text{O}_2 \le 300$ or $235 < S_p\text{O}_2/F_i\text{O}_2 \le 315$), moderate ($100 < P_a\text{O}_2/F_i\text{O}_2 \le 200$ or $148 < S_p\text{O}_2/F_i\text{O}_2 \le 235$), or severe ($P_a\text{O}_2/F_i\text{O}_2 \le 100$ or $S_p\text{O}_2/F_i\text{O}_2 \le 148$).
• Imaging: Bilateral opacities on chest radiograph or CT, or bilateral B-lines and/or consolidation on lung ultrasound performed by a trained operator.
• Resource-limited settings: Neither PEEP, a minimum oxygen flow rate, nor a specific respiratory support device is required; $S_p\text{O}_2/F_i\text{O}_2 \le 315$ with bilateral opacities is sufficient.

---

Triphasic Pathophysiology of ARDS

The morphological hallmark of ARDS is diffuse alveolar damage (DAD), which evolves through three continuous, overlapping phases:

1. Exudative Phase (Days 0–7)

• Alveolar-Capillary Barrier Disruption: Activation of resident pulmonary macrophages triggers release of pro-inflammatory cytokines (tumor necrosis factor-alpha [TNF-$\alpha$], interleukin-1beta [IL-1$\beta$], and interleukin-8 [CXCL8]), recruiting activated neutrophils into the interstitium and alveoli.
• Endothelial and Epithelial Necrosis: Neutrophil proteases and reactive oxygen species cause widespread microvascular endothelial permeability and necrosis of alveolar type I pneumocytes (which cover $90\%$ of the alveolar surface).
• Protein-Rich Flooding and Hyaline Membranes: Extravasation of protein-rich fluid into the alveolar space inactivates pulmonary surfactant. Denuded basement membranes become coated with fibrin, cellular debris, and plasma proteins, forming eosinophilic hyaline membranes.
• Microvascular Thrombosis: Platelet activation and fibrin deposition within the pulmonary capillary bed create microvascular occlusions, increasing physiological dead space ($V_D/V_T$) and precipitating acute pulmonary hypertension.

2. Proliferative Phase (Days 7–21)

• Epithelial Repair: Marked hyperplasia and proliferation of type II pneumocytes along the denuded alveolar basement membranes. These cells act as progenitor stem cells, differentiating into type I pneumocytes to restore the epithelial barrier and re-establish active sodium and water transport via apical epithelial sodium channels ($ENaC$) and basolateral $Na^+/K^+$-ATPase pumps.
• Fibroblast Activation: Infiltration of fibroblasts and myofibroblasts produces provisional fibronectin and early collagen matrices, transforming the exudative fluid into organizing cellular granulation tissue.

3. Fibrotic Phase (>21 Days)

• Structural Remodeling: Observed in a subset of patients with unresolving disease; characterized by extensive collagen deposition, parenchymal architectural distortion, and subpleural cyst or bulla formation.
• Microvascular Obliteration: Permanent loss of microvascular beds leads to chronic pulmonary vascular resistance elevation, refractory hypercapnia, and irreversible reductions in static respiratory compliance ($C_{\text{rs}}$).

---

Mechanical Ventilation Modes: Comparison and Mechanics

Selecting an appropriate mechanical ventilation mode in ARDS balances the necessity of providing reliable alveolar minute ventilation against the hazard of cyclic mechanical stress.

---

Ventilator-Induced Lung Injury (VILI)

Inappropriate ventilator settings directly aggravate preexisting alveolar injury, culminating in Ventilator-Induced Lung Injury (VILI) through four distinct mechanisms:

1. Barotrauma: Gross air leaks (pneumothorax, pneumomediastinum, subcutaneous emphysema) resulting from excessive transalveolar pressure gradients exceeding the structural tension limits of the alveolar wall.
2. Volutrauma: High end-inspiratory alveolar volume causing regional overdistension and disruption of alveolar-capillary integrity. Volutrauma is driven by absolute volume distension rather than airway pressure alone.
3. Atelectrauma: Low end-expiratory alveolar volume leading to repetitive cyclic opening, collapse, and reopening of unstable, surfactant-deficient alveoli. The resulting liquid-bridge shear forces strip away the surfactant film and tear the alveolar epithelium.
4. Biotrauma: Mechanotransduction: physical strain and shear stress activate cellular signaling cascades in alveolar macrophages and epithelial cells, stimulating the release of inflammatory cytokines (IL-1$\beta$, IL-6, TNF-$\alpha$, CXCL8). These mediators enter the systemic circulation via disrupted capillaries, driving systemic inflammatory response syndrome (SIRS), hemodynamic collapse, and Multi-Organ Dysfunction Syndrome (MODS).

---

The ARDSNet Lung-Protective Ventilation Strategy

The landmark ARDS Network (ARMA) trial established that ventilating with lower tidal volumes significantly reduces mortality compared to traditional ventilation ($31.0\%$ vs $39.8\%$, $p = 0.007$).

1. Predicted Body Weight (PBW)

Tidal volume must be calculated strictly according to Predicted Body Weight (PBW) based on patient height and sex, rather than actual body weight. Actual body weight overestimates lung volume—particularly in obese individuals—because lung size correlates with skeletal height, not adipose mass (the "baby lung" concept introduced by Gattinoni, where functional aerated lung in ARDS equals that of a normal 5-to-6-year-old child).

$\text{PBW (Males)} = 50 + 0.91 \times (\text{Height in cm} - 152.4)$ $\text{PBW (Females)} = 45.5 + 0.91 \times (\text{Height in cm} - 152.4)$

• Initial Target: $6\text{ mL/kg}$ of PBW (titratable between $4\text{ and }8\text{ mL/kg}$ PBW based on plateau pressure and pH).

2. Plateau Pressure Limit ($P_{\text{plat}}$)

Plateau pressure reflects end-inspiratory static alveolar distending pressure and is measured during a $0.5\text{-second}$ end-inspiratory occlusion hold:

$P_{\text{plat}} \le 30\text{ cm}\text{H}_2\text{O}$

If $P_{\text{plat}} > 30\text{ cm}\text{H}_2\text{O}$, tidal volume must be decreased by $1\text{ mL/kg}$ PBW decrements down to a minimum of $4\text{ mL/kg}$ PBW.

3. Driving Pressure ($\Delta P$)

Amato et al. demonstrated that driving pressure is the physiological parameter most strongly associated with survival in ARDS:

$\Delta P = P_{\text{plat}} - \text{PEEP} = \frac{V_T}{C_{\text{rs}}}$

Driving pressure normalizes tidal volume to functional respiratory system compliance ($C_{\text{rs}}$), reflecting the true strain on the aerated "baby lung." Clinicians should maintain $\Delta P < 14-15\text{ cm}\text{H}_2\text{O}$. Reductions in $\Delta P$ achieved by adjusting PEEP or $V_T$ correlate directly with improved hospital survival.

4. PEEP Titration and Permissive Hypercapnia

• PEEP Titration: Applied according to high or low PEEP/$F_i\text{O}_2$ tables (or decremental PEEP titration following a recruitment maneuver) to maintain alveolar patency at end-expiration, prevent atelectrauma, and reduce intrapulmonary shunt.
• Permissive Hypercapnia: Because low tidal volume ventilation reduces alveolar minute ventilation, $P_a\text{CO}_2$ is permitted to rise, accepting an arterial pH as low as $7.20-7.25$.
• Absolute and Relative Contraindications to Permissive Hypercapnia:
  1. Elevated intracranial pressure (ICP) or acute traumatic brain injury (hypercapnia causes cerebral vasodilation, increasing intracranial volume and pressure);
  2. Severe pulmonary arterial hypertension or acute right ventricular failure (hypercapnia and acidemia trigger intense pulmonary vasoconstriction, precipitating acute cor pulmonale);
  3. Severe hemodynamic instability or uncorrected metabolic acidosis;
  4. Acute coronary syndrome (acidemia reduces myocardial contractility and lowers dysrhythmia thresholds).

---

Evidence-Based Adjunctive Therapies in Severe ARDS

Moderate-to-Severe ARDS (P/F < 150 mmHg on PEEP >= 5)
  ├── Lung-Protective Ventilation (VT 6 mL/kg PBW, Pplat <= 30, Driving Pressure < 14)
  ├── Early Prone Positioning (>= 16 hours/day) ────── [PROSEVA Trial: Proven Mortality Reduction]
  ├── Neuromuscular Blockade (selected patients) ──── [ROSE 2019: No Routine Mortality Benefit]
  ├── Inhaled Pulmonary Vasodilators (iNO / Epoprostenol) ── [Improves Oxygenation; No Mortality Benefit]
  └── Refractory Hypoxemia (P/F < 80 mmHg) ────────── [VV-ECMO: EOLIA / CESAR Criteria]

1. Prone Positioning (The PROSEVA Trial)

The PROSEVA trial demonstrated that in patients with severe ARDS ($P_a\text{O}_2/F_i\text{O}_2 < 150\text{ mmHg}$ with PEEP $\ge 5\text{ cm}\text{H}_2\text{O}$, $F_i\text{O}_2 \ge 0.60$), early and prolonged prone positioning for at least 16 consecutive hours per day reduced 28-day mortality from $32.8\%$ to $16.0\%$ ($p < 0.001$) and 90-day mortality from $41.0\%$ to $23.6\%$.

• Physiological Mechanisms:
  • Homogenization of Transpulmonary Pressure: In the supine position, the weight of ventral lung tissue, the heart, and abdominal contents causes a steep ventral-to-dorsal pleural pressure gradient, compressing dependent dorsal lung regions. In the prone position, the vertical gradient of transpulmonary pressure ($P_{\text{tp}} = P_{\text{alv}} - P_{\text{pl}}$) becomes uniform, leading to homogeneous alveolar inflation.
  • Ventilation-Perfusion ($V/Q$) Matching: Pulmonary perfusion remains preferentially distributed to dorsal lung segments regardless of body position due to vascular anatomical architecture. By opening dependent dorsal alveoli while maintaining dorsal blood flow, ventilation-perfusion mismatch and intrapulmonary shunting are substantially reduced.
  • Reduced Lung Strain: By recruiting dorsal units, the volume of aerated lung increases, lowering regional driving pressure and mitigating VILI.

2. Neuromuscular Blockade (The ACURASYS and ROSE Trials)

• ACURASYS Trial: Early 48-hour continuous infusion of cisatracurium besylate in severe ARDS ($P_a\text{O}_2/F_i\text{O}_2 < 150\text{ mmHg}$) improved adjusted 90-day survival and increased ventilator-free days without inducing ICU-acquired muscle weakness.
• Mechanisms: Complete paralysis eliminates patient-ventilator dyssynchrony (e.g., breath-stacking, double triggering, reverse triggering), abolishes violent transpulmonary pressure swings (such as occult pendelluft—intrapulmonary gas movement between lung units), and lowers total-body systemic oxygen consumption.
• ROSE (PETAL Network) Trial: When light sedation was protocolized, early continuous neuromuscular blockade showed no mortality difference compared to a strategy of deep sedation with targeted, intermittent paralysis. The 2023 ESICM ARDS guideline recommends against routine continuous neuromuscular blockade; a short course (about $24-48\text{ hours}$) is reserved for selected patients with persistent patient-ventilator dyssynchrony, refractory hypoxaemia, or high driving pressure despite optimised analgesia and sedation.

3. Inhaled Pulmonary Vasodilators

• Inhaled Nitric Oxide (iNO) and Inhaled Prostacyclin (Epoprostenol): Delivered directly into the inspiratory limb of the breathing circuit. These agents act selectively on smooth muscle in ventilated alveolar units, causing localized vasodilation.
• Physiology: Redirects pulmonary blood flow away from non-aerated, consolidated lung regions toward well-ventilated units, decreasing physiological shunt fraction and improving arterial oxygenation without inducing systemic hypotension.
• Clinical Outcome: Meta-analyses show rapid, temporary improvements in $P_a\text{O}_2/F_i\text{O}_2$, but no reduction in overall mortality or duration of mechanical ventilation. Routine use is reserved as a rescue bridge for refractory hypoxemic crises.

4. Extracorporeal Membrane Oxygenation (ECMO)

• Venovenous (VV) ECMO: Indicated for severe, refractory hypoxemic respiratory failure where lung-protective ventilation cannot maintain gas exchange without hazardous airway pressures. The EOLIA trial entry criteria, applied despite optimised ventilation (including prone positioning where possible), were $P_a\text{O}_2/F_i\text{O}_2 < 50\text{ mmHg}$ for $>3\text{ hours}$, $P_a\text{O}_2/F_i\text{O}_2 < 80\text{ mmHg}$ for $>6\text{ hours}$, or $pH < 7.25$ with $P_a\text{CO}_2 \ge 60\text{ mmHg}$ for $>6\text{ hours}$.
• Venoarterial (VA) ECMO: Drains venous blood and returns oxygenated blood to the arterial system, providing simultaneous circulatory and respiratory support in combined acute cardiopulmonary failure (e.g., refractory cardiogenic shock with ARDS or acute massive pulmonary embolism).

---

Clinical Pearls and Exam Traps

• Actual vs Predicted Body Weight Trap: Never use actual body weight to calculate tidal volume in ARDS. In an obese patient weighing $120\text{ kg}$ with a PBW of $70\text{ kg}$, setting $6\text{ mL/kg}$ based on actual weight ($720\text{ mL}$) yields an effective tidal volume of $>10\text{ mL/kg}$ PBW, producing massive volutrauma and accelerating patient mortality.
• Peak vs Plateau Pressure Distinction: $P_{\text{peak}}$ reflects total airway resistance plus respiratory system elastance ($P_{\text{peak}} = \text{Flow} \times R_{\text{aw}} + P_{\text{plat}}$). A high $P_{\text{peak}}$ with a normal $P_{\text{plat}}$ indicates an airway resistance problem (e.g., endotracheal tube kinking, bronchospasm, mucus plugging). A high $P_{\text{plat}}$ indicates decreased thoracic or lung compliance (e.g., worsening ARDS, pneumothorax, abdominal compartment syndrome).
• Prone Positioning Timing: Prone positioning must be implemented early (within the first $24-48\text{ hours}$ of moderate-to-severe ARDS diagnosis) and continued for at least $16\text{ consecutive hours}$ per session. Intermittent brief prone turns ($<12\text{ hours}$) do not confer a mortality benefit.